These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6398020)

  • 21. Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.
    Milanese C; Salmaggi A; La Mantia L; Campi A; Eoli M; Savoiardo M; Bianchi G; Nespolo A
    J Neurol Neurosurg Psychiatry; 1990 Jul; 53(7):554-7. PubMed ID: 1697334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of T-hairy cell leukemia with lymphoblastoid-interferon.
    Rossi E; Gualandi F; Lamparelli T; Repetto M; Nocera A; Spriano M; Occhini D; Ruggeri C; Vimercati R; Damasio EE
    J Exp Pathol; 1987; 3(4):593-601. PubMed ID: 3502652
    [No Abstract]   [Full Text] [Related]  

  • 23. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls.
    Kreuzfelder E; Shen G; Bittorf M; Scheiermann N; Thraenhart O; Seidel D; Grosse-Wilde H
    Eur Neurol; 1992; 32(4):190-4. PubMed ID: 1505587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma.
    Krown SE; Real FX; Cunningham-Rundles S; Myskowski PL; Koziner B; Fein S; Mittelman A; Oettgen HF; Safai B
    N Engl J Med; 1983 May; 308(18):1071-6. PubMed ID: 6835320
    [No Abstract]   [Full Text] [Related]  

  • 25. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis.
    Mora JS; Munsat TL; Kao KP; Finison LJ; Hedlund W; Bradley GA; Scheife R; Georgiades JA
    Neurology; 1986 Aug; 36(8):1137-40. PubMed ID: 3526180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of interferon-alpha on human warts.
    Pazin GJ; Ho M; Haverkos HW; Armstrong JA; Breinig MC; Wechsler HL; Arvin A; Merigan TC; Cantell K
    J Interferon Res; 1982; 2(2):235-43. PubMed ID: 7119508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant leukocyte A interferon in Kaposi's sarcoma.
    Krown SE; Real FX; Krim M; Cunningham-Rundles S; Koziner B; Myskowski PL; Safai B; Oettgen HF
    Ann N Y Acad Sci; 1984; 437():431-8. PubMed ID: 6398651
    [No Abstract]   [Full Text] [Related]  

  • 28. Double-blind trial of linoleic acid in multiple sclerosis.
    Paty DW
    Arch Neurol; 1983 Oct; 40(11):693-4. PubMed ID: 6354153
    [No Abstract]   [Full Text] [Related]  

  • 29. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy.
    Vonderheid EC; Thompson R; Smiles KA; Lattanand A
    Arch Dermatol; 1987 Jun; 123(6):757-63. PubMed ID: 3579357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current therapy of multiple sclerosis: "T-cell vaccination"].
    Zipp F; Hohlfeld R
    Nervenarzt; 1994 Jun; 65(6):424-5. PubMed ID: 8072598
    [No Abstract]   [Full Text] [Related]  

  • 31. [Multiple sclerosis].
    Tanosaki M; Matsunaga M
    Nihon Rinsho; 2004 May; 62 Suppl 5():586-9. PubMed ID: 15197989
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial.
    Barnes MP; Bates D; Cartlidge NE; French JM; Shaw DA
    J Neurol Neurosurg Psychiatry; 1987 Nov; 50(11):1402-6. PubMed ID: 3320274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol.
    Mandelli F; Tribalto M; Avvisati G; Cantonetti M; Petrucci MT; Boccadoro M; Pileri A; Marmont F; Resegotti L; Lauta V
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():43-8. PubMed ID: 3277709
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis.
    Pompidou A; Rancurel G; Delsaux MC; Meunier C; Telvi L; Cour V; Buge A
    Cancer Detect Prev Suppl; 1987; 1():377-83. PubMed ID: 2446758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interferon therapy in multiple sclerosis. Mechanism of action, side effects, results].
    Huber M
    Nervenarzt; 1988 Sep; 59(9):514-20. PubMed ID: 2460777
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of hemosorption in disseminated sclerosis].
    Golovkin VI; Pershin VN; Tulenko AG
    Vrach Delo; 1986 Feb; (2):84-6. PubMed ID: 3486528
    [No Abstract]   [Full Text] [Related]  

  • 37. Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Liu Q; Shi FD
    Mult Scler; 2019 Apr; 25(4):512-513. PubMed ID: 30421642
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study.
    O'Connell MJ; Colgan JP; Oken MM; Ritts RE; Kay NE; Itri LM
    J Clin Oncol; 1986 Feb; 4(2):128-36. PubMed ID: 3511183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Laroni A
    Mult Scler; 2019 Apr; 25(4):510-512. PubMed ID: 30421641
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.